Loading...

Tabula Rasa HealthCare

DB:43T
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
43T
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the field of medication safety in the United States. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print
  • Tabula Rasa HealthCare has significant price volatility in the past 3 months.
43T Share Price and Events
7 Day Returns
-11.1%
DB:43T
-1.8%
DE Healthcare Services
1.8%
DE Market
1 Year Returns
29%
DB:43T
21%
DE Healthcare Services
-6%
DE Market
43T Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Tabula Rasa HealthCare (43T) -11.1% -26.4% -27.8% 29% - -
DE Healthcare Services -1.8% 3.4% 19.8% 21% 50.2% 158.6%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 43T outperformed the Healthcare Services industry which returned 21% over the past year.
  • 43T outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
43T
Industry
5yr Volatility vs Market
Related Companies

43T Value

 Is Tabula Rasa HealthCare undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Tabula Rasa HealthCare to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Tabula Rasa HealthCare.

DB:43T Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:43T
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.21
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.215 (1 + (1- 21%) (4.28%))
1.171
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.17
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.171 * 5.96%)
7.21%

Discounted Cash Flow Calculation for DB:43T using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Tabula Rasa HealthCare is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:43T DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.21%)
2019 -7.40 Analyst x3 -6.90
2020 27.18 Analyst x3 23.65
2021 56.30 Analyst x1 45.69
2022 77.40 Analyst x1 58.59
2023 93.40 Analyst x1 65.95
2024 105.72 Est @ 13.19% 69.63
2025 115.56 Est @ 9.3% 70.99
2026 123.16 Est @ 6.58% 70.57
2027 128.92 Est @ 4.67% 68.90
2028 133.22 Est @ 3.34% 66.42
Present value of next 10 years cash flows $533.49
DB:43T DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $133.22 × (1 + 0.23%) ÷ (7.21% – 0.23%)
$1,912.88
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,912.88 ÷ (1 + 7.21%)10
$953.67
DB:43T Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $533.49 + $953.67
$1,487.16
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,487.16 / 21.74
$68.4
DB:43T Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:43T represents 0.86953x of NasdaqGM:TRHC
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86953x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 68.40 x 0.86953
€59.47
Value per share (EUR) From above. €59.47
Current discount Discount to share price of €43.12
= -1 x (€43.12 - €59.47) / €59.47
27.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Tabula Rasa HealthCare is available for.
Intrinsic value
27%
Share price is €43.12 vs Future cash flow value of €59.47
Current Discount Checks
For Tabula Rasa HealthCare to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Tabula Rasa HealthCare's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Tabula Rasa HealthCare's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Tabula Rasa HealthCare's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Tabula Rasa HealthCare's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:43T PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.48
NasdaqGM:TRHC Share Price ** NasdaqGM (2019-04-18) in USD $49.59
Germany Healthcare Services Industry PE Ratio Median Figure of 5 Publicly-Listed Healthcare Services Companies 29.34x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Tabula Rasa HealthCare.

DB:43T PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:TRHC Share Price ÷ EPS (both in USD)

= 49.59 ÷ -2.48

-20.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tabula Rasa HealthCare is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Tabula Rasa HealthCare is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Tabula Rasa HealthCare's expected growth come at a high price?
Raw Data
DB:43T PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -20.04x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
126.3%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Tabula Rasa HealthCare, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Tabula Rasa HealthCare's assets?
Raw Data
DB:43T PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $6.76
NasdaqGM:TRHC Share Price * NasdaqGM (2019-04-18) in USD $49.59
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.08x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:43T PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:TRHC Share Price ÷ Book Value per Share (both in USD)

= 49.59 ÷ 6.76

7.33x

* Primary Listing of Tabula Rasa HealthCare.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tabula Rasa HealthCare is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Tabula Rasa HealthCare's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Tabula Rasa HealthCare has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

43T Future Performance

 How is Tabula Rasa HealthCare expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
126.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Tabula Rasa HealthCare expected to grow at an attractive rate?
  • Tabula Rasa HealthCare's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Tabula Rasa HealthCare's earnings growth is expected to exceed the Germany market average.
  • Tabula Rasa HealthCare's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:43T Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:43T Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 126.3%
DB:43T Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 18.3%
Germany Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 6.2%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 7.4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:43T Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:43T Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 553 1
2022-12-31 481 1
2021-12-31 415 3
2020-12-31 351 34 1 10
2019-12-31 285 -13 -10 10
DB:43T Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 204 16 -47
2018-09-30 191 16 -24
2018-06-30 170 15 -29
2018-03-31 151 17 -1
2017-12-31 133 18 13
2017-09-30 117 16 -3
2017-06-30 109 7 -8
2017-03-31 102 4 -7
2016-12-31 95 7 -3
2016-09-30 87 3 4
2016-06-30 80 9 -11
2016-03-31 75 7 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Tabula Rasa HealthCare's earnings are expected to grow significantly at over 20% yearly.
  • Tabula Rasa HealthCare's revenue is expected to grow by 18.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:43T Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Tabula Rasa HealthCare Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:43T Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.08 0.57 -0.34 6.00
2019-12-31 -0.42 -0.32 -0.47 7.00
DB:43T Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.48
2018-09-30 -1.31
2018-06-30 -1.59
2018-03-31 -0.07
2017-12-31 0.76
2017-09-30 -0.18
2017-06-30 -0.59
2017-03-31 -0.65
2016-12-31 -0.41
2016-09-30 0.89
2016-06-30 -2.42
2016-03-31 -2.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Tabula Rasa HealthCare will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Tabula Rasa HealthCare's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Tabula Rasa HealthCare has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

43T Past Performance

  How has Tabula Rasa HealthCare performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Tabula Rasa HealthCare's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Tabula Rasa HealthCare does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Tabula Rasa HealthCare's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Tabula Rasa HealthCare's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Tabula Rasa HealthCare's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Tabula Rasa HealthCare Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:43T Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 204.27 -47.27 35.95 12.22
2018-09-30 191.36 -24.30 32.34 10.11
2018-06-30 169.67 -28.55 27.64 8.25
2018-03-31 150.51 -1.21 25.91 6.62
2017-12-31 133.49 12.79 25.80 5.63
2017-09-30 117.46 -3.00 27.44 4.97
2017-06-30 108.90 -7.81 24.95 4.47
2017-03-31 101.88 -6.70 20.82 4.14
2016-12-31 94.79 -3.08 15.75 3.81
2016-09-30 86.51 4.26 10.82 3.88
2016-06-30 80.29 -11.17 10.68 3.54
2016-03-31 74.69 -11.84 10.45 3.21
2015-12-31 70.04 -12.83 10.00 2.88
2015-09-30 64.03 -20.21 9.97 1.87
2015-06-30 59.09 -6.31 8.69 1.54
2015-03-31 53.10 -5.38 7.61 1.30
2014-12-31 48.43 -4.99 6.24 1.66
2013-12-31 25.14 -9.22 4.69 0.91

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Tabula Rasa HealthCare has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Tabula Rasa HealthCare has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Tabula Rasa HealthCare improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Tabula Rasa HealthCare's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Tabula Rasa HealthCare has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

43T Health

 How is Tabula Rasa HealthCare's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Tabula Rasa HealthCare's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Tabula Rasa HealthCare's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Tabula Rasa HealthCare's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Tabula Rasa HealthCare's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Tabula Rasa HealthCare Company Filings, last reported 3 months ago.

DB:43T Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 139.01 46.10 20.28
2018-09-30 97.60 27.87 13.95
2018-06-30 80.18 9.64 7.27
2018-03-31 105.77 1.89 4.25
2017-12-31 123.89 1.71 10.43
2017-09-30 75.97 36.95 5.94
2017-06-30 55.78 1.46 2.81
2017-03-31 55.13 1.63 2.81
2016-12-31 56.11 1.75 4.35
2016-09-30 2.57 46.56 1.79
2016-06-30 3.12 43.43 4.30
2016-03-31 3.15 41.10 2.29
2015-12-31 2.91 39.83 2.03
2015-09-30 2.41 40.26 2.56
2015-06-30 1.82 40.25 2.65
2015-03-31 1.79 37.33 4.12
2014-12-31 1.79 37.33 4.12
2013-12-31 -0.22 11.18 6.03
  • Tabula Rasa HealthCare's level of debt (33.2%) compared to net worth is satisfactory (less than 40%).
  • Tabula Rasa HealthCare had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Tabula Rasa HealthCare has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Tabula Rasa HealthCare has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -51.6% per year.
X
Financial health checks
We assess Tabula Rasa HealthCare's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Tabula Rasa HealthCare has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

43T Dividends

 What is Tabula Rasa HealthCare's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Tabula Rasa HealthCare dividends. Estimated to be 0% next year.
If you bought €2,000 of Tabula Rasa HealthCare shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Tabula Rasa HealthCare's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Tabula Rasa HealthCare's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:43T Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:43T Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Tabula Rasa HealthCare has not reported any payouts.
  • Unable to verify if Tabula Rasa HealthCare's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Tabula Rasa HealthCare's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Tabula Rasa HealthCare has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Tabula Rasa HealthCare's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Tabula Rasa HealthCare's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Tabula Rasa HealthCare afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Tabula Rasa HealthCare has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

43T Management

 What is the CEO of Tabula Rasa HealthCare's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Calvin Knowlton
COMPENSATION $1,693,069
AGE 68
TENURE AS CEO 4.8 years
CEO Bio

Dr. Calvin H. Knowlton, BSc Pharm, MDiv, Ph.D., is a Co-Founder of Tabula Rasa Healthcare, Inc. and has been its Chairman and Chief Executive Officer since June 2014. Dr. Knowlton founded CareKinesis, Inc. and serves as its Chairman and Chief Executive Officer since May 2009. Dr. Knowlton founded Enclara Pharmacia, Inc. (formerly excelleRx, Inc.) in 1996 and served as its President and Chief Executive Officer from 1995 to 2007. He has owned and managed four companies prior to excelleRx, Inc. He chairs the Board of Coriell Life Sciences, Inc., and serves on the Board of the Cooper Medical School of Rowan University. He serves on the Board of the Coriell Institute for Medical Research and the Evergreens Continuing Care Retirement Community. He serves on the Board (Session) of the First Presbyterian Church in Moorestown NJ and chairs their Long Range Planning Panel. He finished his term on the Board of St Christopher’s Hospital for Children in Philadelphia. He is a member of the APhA Pharmacogenomics Task Force, as well as the FDA-recognized National Pharmacogenomics Advisory Group from 2011 to 2012. He served as Professor and Department Chair for the University of the Sciences in Philadelphia in the 1990s. He has been elected and served as the National President for the American College of Apothecaries and the American Pharmacists Association from 1994 to 1996, and President of the American Pharmacist Association Foundation from 2008 to 2009. He was selected as the Most Influential U.S. Pharmacist in 1997. Dr. Knowlton, initiator of excelleRx, Inc. He has published widely, including a textbook, Pharmaceutical Care. In recognition of his accomplishments over a 30-year career, he has won several awards for innovation and leadership in pharmacy, business and philanthropy, including Ernest & Young Entrepreneur of the Year 2003 and 2013, Walter M. Aikman Entrepreneur of the Year 2004 and Most Influential Pharmacist in the U.S. in 1997. Dr. Knowlton was also awarded the highest national honor in pharmacy, the Remington Honor Medal, in 2015. Dr. Knowlton received his BA from Rider College, Bachelor of Science degree in pharmacy from Temple University, Philadelphia, PA; Masters in Divinity from Princeton University and PhD in Pharmacoeconomics from the University of Maryland.

CEO Compensation
  • Calvin's compensation has been consistent with company performance over the past year.
  • Calvin's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Tabula Rasa HealthCare management team in years:

4.5
Average Tenure
52
Average Age
  • The tenure for the Tabula Rasa HealthCare management team is about average.
Management Team

Calvin Knowlton

TITLE
Co-Founder
COMPENSATION
$2M
AGE
68
TENURE
4.8 yrs

Orsula Knowlton

TITLE
Co-Founder
COMPENSATION
$1M
AGE
49
TENURE
4.8 yrs

Brian Adams

TITLE
CFO & Secretary
COMPENSATION
$882K
AGE
36
TENURE
4.8 yrs

Michael Greenhalgh

TITLE
Chief Operating Officer
TENURE
4.8 yrs

Andrea Speers

TITLE
Corporate Controller & Chief Accounting Officer
AGE
36
TENURE
1.2 yrs

Tom Wilson

TITLE
Chief Technology Innovation Officer & EVP of eHealth Services
TENURE
0.3 yrs

Joseph Filippoli

TITLE
Chief Information Officer
AGE
52
TENURE
4.8 yrs

Jacques Turgeon

TITLE
Chief Scientific Officer
AGE
58
TENURE
3.6 yrs

Phillip Heath

TITLE
Chief Administrative Officer
AGE
52
TENURE
4.2 yrs

Kevin Dill

TITLE
General Counsel
TENURE
2.5 yrs
Board of Directors Tenure

Average tenure and age of the Tabula Rasa HealthCare board of directors in years:

1.2
Average Tenure
65
Average Age
  • The average tenure for the Tabula Rasa HealthCare board of directors is less than 3 years, this suggests a new board.
Board of Directors

Calvin Knowlton

TITLE
Co-Founder
COMPENSATION
$2M
AGE
68
TENURE
4.8 yrs

Orsula Knowlton

TITLE
Co-Founder
COMPENSATION
$1M
AGE
49

A. Tunstall

TITLE
Independent Director
COMPENSATION
$75K
AGE
74
TENURE
4.8 yrs

Dennis Helling

TITLE
Independent Director
COMPENSATION
$237K
AGE
69
TENURE
2.1 yrs

Samira Beckwith

TITLE
Independent Director
COMPENSATION
$216K
AGE
65
TENURE
1.7 yrs

Michael Purcell

TITLE
Director
AGE
60
TENURE
0.8 yrs

Jan Berger

TITLE
Director
TENURE
0.8 yrs

Kathrine O'brien

TITLE
Director
TENURE
0.4 yrs

Pamela Schweitzer

TITLE
Director
AGE
58
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Jan 19 Sell Brian Adams Individual 03. Jan 19 03. Jan 19 -3,035 €50.37 €-152,862
04. Jan 19 Sell Andrea Speers Individual 03. Jan 19 03. Jan 19 -1,022 €50.92 €-52,039
14. Dec 18 Sell Samira Beckwith Individual 12. Dec 18 12. Dec 18 -1,733 €66.69 €-115,576
14. Nov 18 Buy Calvin Knowlton Individual 12. Nov 18 12. Nov 18 7,500 €58.47 €433,413
22. May 18 Sell Rittenhouse Ventures, LLC Company 18. May 18 22. May 18 -85,842 €44.43 €-3,690,873
18. May 18 Sell Glen Bressner Individual 16. May 18 17. May 18 -52,165 €43.14 €-2,198,514
17. May 18 Sell Rittenhouse Ventures, LLC Company 16. May 18 17. May 18 -32,431 €42.73 €-1,351,595
15. May 18 Sell Rittenhouse Ventures, LLC Company 11. May 18 15. May 18 -67,569 €41.48 €-2,733,133
X
Management checks
We assess Tabula Rasa HealthCare's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Tabula Rasa HealthCare has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

43T News

Simply Wall St News

43T Company Info

Description

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the field of medication safety in the United States. The company’s proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems. The company’s cloud-based software applications also comprise RxCompanion, a medication therapy management software platform for the identification and resolution of medication and other health related problems; TruChart, an electronic health record (EHR) system for Programs of All-Inclusive Care for the Elderly (PACE) programs; and PACElogic, which deliver real-time sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination, planning, integration with community-based providers, and various Federal and State required reporting for PACE organizations and small health plans. Tabula Rasa HealthCare, Inc. also offers clinical pharmacist collaboration, prescription fulfillment and reminder packaging, and pharmacy cost management services, as well as health plan management services, including risk adjustment and third party administrator services. As of December 31, 2018, it served 224 healthcare organizations. The company offers its cloud-based software solutions to prescribers, pharmacists, and healthcare organizations for managing the medication-related needs of their patients. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.

Details
Name: Tabula Rasa HealthCare, Inc.
43T
Exchange: DB
Founded: 2009
$957,682,357
21,742,857
Website: http://www.tabularasahealthcare.com
Address: Tabula Rasa HealthCare, Inc.
228 Strawbridge Drive,
Suite 100,
Moorestown,
New Jersey, 08057,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM TRHC Common Stock Nasdaq Global Market US USD 29. Sep 2016
DB 43T Common Stock Deutsche Boerse AG DE EUR 29. Sep 2016
Number of employees
Current staff
Staff numbers
952
Tabula Rasa HealthCare employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:30
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.